Loading...
XSHG
688265
, Last price  
Name

Shanghai Model Organisms Center Inc

Chart & performance

D1W1MN
XSHG:688265 chart
P/E
—
P/S
—
EPS
0.40
Vol. 1Y
—
Shs. 5Y
5.72%
Rev. 5Y
16.51%
Div Yld LY
—
Div Yld TTM
—
Revenues
421m
+10.50%
45,403,16160,517,01776,291,300121,442,167154,802,855196,190,409275,268,954302,965,239366,548,781381,239,513421,258,600
Net income
31m
+383.97%
10,598,77414,622,658-16,053,40015,111,23623,249,90844,555,91760,860,908-5,399,639-20,582,6056,495,50431,436,529
CFO
97m
+35.43%
20,426,20425,833,3728,233,59311,745,70834,771,06759,102,989111,457,50418,893,41620,082,24771,564,01996,919,246
Dividend
Jul 13, 20260.125 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Model Organisms Center, Inc. (SMOC) is a prominent Chinese enterprise dedicated to the research and development of genetically engineered animal models. The company offers a broad spectrum of specialized rodent models, encompassing disease-specific, humanized, immunodeficient, tool, and fluorescent reporter strains of both mice and rats. Furthermore, SMOC produces custom cellular products, including fluorescently labeled, primary, and humanized cell lines. Beyond its core product offerings, SMOC delivers a comprehensive suite of support services. These include personalized model generation, animal husbandry and breeding programs, in-depth phenotypic analysis, and critical drug screening and evaluation services for preclinical research. Established in 2000, SMOC maintains its primary operations and corporate headquarters in Shanghai, China.
IPO date
Dec 28, 2021
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT